Vertical: CNMBase Year: 2025
Market Size (2025)
$380.97M
Projected (2032)
$525.85M
CAGR (2022–2032)
4.7%
Key Players
10+
Market Overview
The global feed antibiotics market was valued at USD 380.97 million in 2025 and is projected to reach USD 525.85 million by 2032, registering a CAGR of 4.71% over the forecast period 2026–2032. The market has expanded steadily from USD 331.73 million in 2022, and the forecast period is expected to add USD 144.87 million in absolute value between 2025 and 2032.
Feed antibiotics are antibacterial agents incorporated into compound feed, premixes and medicated feed to treat, control and prevent bacterial diseases in food-producing animals. Demand is shaped by two opposing forces. On one side, rising consumption of poultry meat, pork and eggs, the intensification of livestock production in Asia, Latin America and Africa, and the recurring burden of enteric and respiratory diseases sustain the need for medicated feed. On the other side, regulation aimed at containing antimicrobial resistance (AMR) has removed growth-promotion uses in the European Union, the United States, Canada, China, Brazil and several other markets, and has placed most medically important molecules under veterinary oversight. As a result, market value increasingly comes from therapeutic and disease-control applications prescribed by veterinarians, rather than from routine low-dose use.
Key Findings
By antibiotic class: Polypeptides & Others is the largest segment, with a 2025 share of 50.0% (USD 190.49 million). Macrolides is the fastest-growing class, at a CAGR of 6.10% over 2026–2032.
By livestock: Poultry is both the largest segment, with a 2025 share of 45.0% (USD 171.44 million), and the fastest-growing, at a CAGR of 5.47%.
By region: Asia Pacific leads the market, with a 2025 share of 55.0% (USD 209.54 million). Middle East & Africa is the fastest-growing region, at a CAGR of 6.10%.
By country: China is the largest country market, valued at USD 121.53 million in 2025, followed by the U.S. at USD 53.49 million. Saudi Arabia is the fastest-growing country, at a CAGR of 7.58%, closely followed by India at 7.50%.
Absolute growth: Between 2025 and 2032, Asia Pacific adds the most value (USD 82.10 million), and Poultry is the largest contributor among livestock segments (USD 77.65 million).
Segmentation Summary
The market is segmented by antibiotic class into Tetracyclines, Macrolides and Polypeptides & Others; by livestock into Poultry, Swine and Others; and by region into North America, Europe, Asia Pacific, Latin America and Middle East & Africa, with country-level coverage within each region.
Polypeptides & Others accounted for USD 190.49 million in 2025 and is expected to reach USD 265.00 million by 2032. The segment benefits from its broad composition: it includes bacitracin, enramycin, virginiamycin, avilamycin and pleuromutilins, several of which are not classified as critically important for human medicine. Tetracyclines, valued at USD 114.29 million in 2025, remain the workhorse therapeutic class for swine, cattle and poultry. However, this class grows at the slowest rate (3.49%), because chlortetracycline and oxytetracycline are mature, high-volume generic molecules under continuous stewardship pressure. Macrolides, at USD 76.19 million in 2025, grow fastest (6.10%). Growth is driven by the use of tylosin, tilmicosin and tylvalosin against respiratory and enteric diseases such as mycoplasmosis and ileitis.
By livestock, Poultry is the largest and fastest-growing segment, rising from USD 171.44 million in 2025 to USD 249.09 million in 2032. This reflects the global expansion of broiler and layer production. Swine, at USD 133.34 million in 2025, grows at 3.85% as Asian pig production rebuilds and consolidates. The Others segment, covering cattle, small ruminants, aquaculture and other species, reaches USD 103.09 million by 2032.
Competitive Landscape Summary
The market is moderately consolidated at the top and fragmented in the long tail. A small group of global animal health companies sets the benchmark for registered medicated feed brands, regulatory dossiers and technical service. These include Phibro Animal Health, Elanco Animal Health, Huvepharma and Merck Animal Health. Phibro strengthened its position materially by acquiring the Zoetis medicated feed additive portfolio, a deal completed on 31 October 2024. Alongside these companies, fermentation-based Chinese producers supply a large share of global active ingredient volumes, especially chlortetracycline and macrolides. Jinhe Biotechnology, CPBIO Holding (formerly Chia Tai Enterprises International), Shandong Lukang Pharmaceutical and China Animal Husbandry Industry are among them. Competition centres on cost efficiency in fermentation, breadth of registrations, compliance with veterinary oversight rules, and the ability to bundle antibiotics with vaccines, anticoccidials and nutritional specialties.
Challenges and Opportunities
The principal challenge is regulatory. Growth-promotion claims for medically important antimicrobials have been withdrawn in most major markets. Prophylactic group treatment through medicated feed is prohibited in the European Union under Regulation (EU) 2019/6 and Regulation (EU) 2019/4. Buyers increasingly demand meat produced with reduced or no antibiotic use. Alternatives such as probiotics, enzymes, organic acids, phytogenics and vaccines are also competing for the same feed budget.
At the same time, there are clear opportunities:
Rapidly expanding poultry sectors in India, Saudi Arabia, Southeast Asia and Africa need effective disease control.
Older molecules are being repositioned for therapeutic and metaphylactic use under veterinary supervision.
Product approvals are being extended to new species.
Precision medicated-feed programmes linked to diagnostics are emerging.
Companies with strong regulatory capabilities and integrated stewardship services are best placed to capture this value.
Future Outlook
The market is expected to grow at a CAGR of 4.71% through 2032. Growth will be faster in emerging markets than in mature ones: North America grows at 3.11%, while Latin America and Middle East & Africa grow at 5.38% and 6.10% respectively. Over the forecast period, the market is expected to shift further towards prescription-based, therapeutic medicated feed. Value per unit is likely to rise as manufacturers invest in compliant formulations, quality assurance and documentation. Manufacturers that combine efficient active ingredient supply with stewardship-oriented services and complementary non-antibiotic solutions are expected to gain share.
The Feed Antibiotics Market market is projected to grow at a CAGR of 4.7% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Feed antibiotics are antibacterial veterinary medicinal substances administered to food-producing animals through feed. Typical forms are Type A medicated articles, concentrated premixes or medicated feed manufactured by licensed feed mills, used to treat, control or prevent bacterial infections. The active ingredients are produced mainly by microbial fermentation (for example chlortetracycline, oxytetracycline, tylosin and bacitracin) or by semi-synthesis (for example tilmicosin and tylvalosin). They are then formulated with carriers such as calcium carbonate, rice hulls or wheat middlings into free-flowing premixes for homogeneous incorporation into compound feed.
Included: in-feed antibacterial products from the tetracycline class (chlortetracycline, oxytetracycline, doxycycline premixes); the macrolide class (tylosin, tilmicosin, tylvalosin and related compounds); and polypeptides and other in-feed antibacterials (bacitracin, enramycin, virginiamycin, colistin where permitted, avilamycin, bambermycins, pleuromutilins such as tiamulin, lincosamides and sulfonamide combinations). These are used in poultry, swine and other livestock, including cattle, small ruminants and aquaculture.
Excluded: antibiotics administered by injection, intramammary or topical routes; water-soluble formulations delivered through drinking water; vaccines; and non-antibiotic feed additives such as probiotics, prebiotics, enzymes, organic acids, essential oils and phytogenics. Anticoccidials marketed solely as coccidiostats are also excluded.
Scope of the Study
The study covers the global feed antibiotics market in value terms (USD Million). It provides historic data for 2022–2024, a base year of 2025 and forecasts for 2026–2032, with compound annual growth rates calculated for 2026–2032. The market is analysed by antibiotic class, by livestock and by region, with country-level analysis as follows:
By Antibiotic Class: Tetracyclines; Macrolides; Polypeptides & Others
By Livestock: Poultry; Swine; Others
By Region: North America (U.S., Canada, Mexico); Europe (Germany, U.K., France, Italy, Spain, Rest of Europe); Asia Pacific (China, India, Japan, Rest of Asia Pacific); Latin America (Brazil, Argentina, Rest of Latin America); Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of MEA)
Timeline: Historic years 2022–2024; base year 2025; forecast period 2026–2032
Unit: USD Million
Research Objectives
To estimate and forecast the size of the global feed antibiotics market in value terms from 2022 to 2032.
To analyse the market by antibiotic class (Tetracyclines, Macrolides, Polypeptides & Others) and identify the classes gaining or losing share under antimicrobial stewardship policies.
To assess demand across livestock categories (Poultry, Swine, Others) in relation to production trends and disease pressure.
To evaluate regional and country-level markets and the effect of national regulations on growth promoters, medicated feed and veterinary prescription.
To identify the key drivers, restraints, opportunities, trends and challenges influencing feed antibiotic use.
To examine the value chain from fermentation-based active ingredient production to premix manufacturing, feed milling and farm use.
To profile the competitive environment, including the positioning, product portfolios and strategic developments of leading manufacturers since 2022.
To assess the potential impact of non-antibiotic alternatives on the long-term demand for feed antibiotics.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured, multi-stage research process:
Data mining. Information was collected from secondary sources to build an understanding of feed antibiotic molecules, regulatory frameworks, livestock production and supplier activity.
Model building. A market model was constructed using top-down and bottom-up approaches.
Primary validation. The model was validated through primary interactions with industry participants across the value chain.
Triangulation and forecasting. Final estimates were triangulated and forecast using a factor-based approach that considers regulatory, demand-side and supply-side variables.
All values are expressed in USD Million.
Secondary Research
Secondary research was used to establish the market baseline, identify participants and track regulatory changes. Sources relevant to the feed antibiotics industry include:
Government and regulatory bodies:
Antimicrobial sales and use reports published by the U.S. Food and Drug Administration (Center for Veterinary Medicine), the European Medicines Agency (ESUAvet), the UK Veterinary Medicines Directorate, the Public Health Agency of Canada (CIPARS) and China's Ministry of Agriculture and Rural Affairs.
Notifications and legal texts issued by agricultural and drug regulators in India, Brazil and other markets.
Intergovernmental organisations: the World Organisation for Animal Health (WOAH) annual reports on antimicrobial agents intended for use in animals; FAO livestock and feed statistics; and WHO lists of medically important antimicrobials.
Industry associations: national and international feed manufacturers' associations, animal health industry associations and poultry and pig producer organisations.
Company information: annual reports, regulatory filings, investor presentations, product labels and press releases of feed antibiotic manufacturers and animal health companies.
Trade and scientific literature: feed industry trade journals, veterinary and animal science journals, and conference proceedings on antimicrobial stewardship and alternatives to antibiotics.
Paid databases: trade, company financial and livestock production databases used to track imports and exports of active ingredients and premixes, and production of meat, eggs and feed.
Primary Research
Primary research was conducted through in-depth interviews and structured discussions. The purpose was to validate secondary findings, fill data gaps and gather qualitative insights on pricing, product mix and regulatory impact.
Supply-side respondents: product managers, regional sales heads and regulatory affairs professionals at active ingredient manufacturers, premix producers and animal health companies, as well as distributors of veterinary medicinal products.
Demand-side respondents: nutritionists and veterinarians at integrated poultry and swine producers, feed mill managers, livestock consultants and farm veterinarians.
Objectives: to validate market size and segment splits; to understand prescription and usage patterns by species; to assess the effect of veterinary oversight requirements and antibiotic-free production programmes; and to obtain forward-looking views on demand, pricing and competition.
Market Size Estimation
Top-down approach: The overall animal health and medicated feed market was established for each region and narrowed to feed antibiotics using the share of in-feed antibacterial products. This share was derived from antimicrobial sales surveillance data, company disclosures and expert inputs. Regional totals were then allocated to antibiotic classes and livestock categories.
Bottom-up approach: Country-level demand was estimated from livestock populations and production volumes (broilers, layers, pigs, cattle and farmed fish), compound feed production, the share of feed that is medicated, and the average inclusion rates and prices of the main molecules. Country estimates were aggregated to regional and global totals.
Data triangulation: Results from both approaches were compared and reconciled with supply-side information, including the revenues of leading manufacturers and trade flows of active ingredients. Discrepancies were resolved through additional primary interactions, and the final market size reflects the convergence of all three perspectives.
Forecasting Methodology
The forecast combines historic trend analysis with a factor-based assessment of future market conditions. The factors considered include: projected growth in meat, egg and aquaculture output; the pace of livestock industry consolidation; compound feed production trends; regulatory timelines on growth promoters, prophylaxis and veterinary prescription; antimicrobial reduction targets set by governments and industry; disease outbreaks and herd recovery cycles; raw material and active ingredient price trends; adoption of alternatives to antibiotics.
Each factor was assessed for its direction and magnitude of impact by region and segment. The resulting growth rates were validated with industry experts, and CAGR values are presented for the period 2026–2032.
Base Year, Forecast Period and Currency
Currency: USD Million (values at constant exchange rates)
Assumptions and Limitations
Regulatory frameworks announced as of the base year are assumed to be implemented as scheduled. Unannounced bans or reclassifications of specific molecules are not built into the forecast.
Livestock production is assumed to follow its long-term trend without catastrophic disruption. Localised disease outbreaks such as African swine fever and highly pathogenic avian influenza are reflected through historic patterns.
Prices are assumed to remain broadly stable in real terms, with no major supply shocks in fermentation-based active ingredients.
Market values are estimated at manufacturer selling-price level. Because many companies do not report feed antibiotic revenue separately, company-level figures are estimated from available disclosures.
Antimicrobial use data in several developing markets is incomplete, which increases the uncertainty of country-level estimates in parts of Asia, Latin America and Africa.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The global feed antibiotics market is moderately consolidated at the level of branded, registered products and fragmented at the level of active ingredient supply and regional formulation. A limited number of multinational animal health companies hold extensive portfolios of registered medicated feed products, regulatory dossiers across multiple jurisdictions and technical service networks. In parallel, Chinese fermentation-based producers supply much of the world's chlortetracycline, oxytetracycline, macrolide and polypeptide active ingredients, and numerous regional premix manufacturers in India, Southeast Asia, Latin America and Africa compete on price and local distribution.
Most of the core molecules are off-patent, so competition centres on cost efficiency, product quality and consistency, breadth of registrations, regulatory compliance support, and the ability to offer integrated health programmes that combine antibiotics with vaccines, anticoccidials and nutritional specialties. Portfolio realignment has been a defining theme since 2022. Zoetis exited medicated feed additives through the sale of its portfolio to Phibro Animal Health, completed in October 2024. Elanco divested its aqua business to Merck Animal Health in July 2024. Chinese producers are expanding capacity and integrating backwards into active ingredient production.
Key Player Positioning
Leaders: Phibro Animal Health is a leading specialist in medicated feed additives. Its portfolio, strengthened by the Zoetis acquisition, includes Aureomycin, BMD, Stafac, Terramycin, Mecadox and Aureomix. Elanco Animal Health is a leading global farm animal health company with in-feed brands such as Tylan, Pulmotil, Denagard and the avilamycin products Kavault, Inteprity and Surmax.
Challengers: Huvepharma, a vertically integrated fermentation-based manufacturer with premixes such as Pharmasin, Vetmulin and Tilmovet. Merck Animal Health, which holds a broad livestock portfolio including Aquaflor and enramycin products. Jinhe Biotechnology, the largest global producer of chlortetracycline premix, which sells in the U.S. through Pharmgate Animal Health.
Niche and regional players: ECO Animal Health, specialised in tylvalosin (Aivlosin). Virbac, with doxycycline and amoxicillin premixes and a growing farm-animal presence in Asia. CPBIO Holding, a chlortetracycline and animal health producer linked to the Charoen Pokphand group. Shandong Lukang Pharmaceutical, a supplier of veterinary macrolide and pleuromutilin active ingredients. China Animal Husbandry Industry, a state-linked animal health group expanding into veterinary antibiotic active ingredients.
Threat of New Entrants: Low
Registration of veterinary medicinal products, including residue, safety and efficacy dossiers, requires substantial time and expense.
Large-scale fermentation and GMP-compliant formulation plants require high capital investment, and incumbents have strong economies of scale.
Tightening AMR regulation discourages new investment in antibiotic-only portfolios.
Bargaining Power of Suppliers: Medium
Fermentation inputs such as corn, glucose and soybean meal are widely traded commodities, which limits the power of individual suppliers.
Supply of several key active ingredients is concentrated among a limited number of Chinese producers, giving them pricing power for formulators without their own production.
Environmental controls on fermentation plants can tighten supply and raise prices periodically.
Bargaining Power of Buyers: High
Large integrators and feed mill groups buy in volume and can switch between suppliers of generic molecules.
Many of the core molecules are off-patent and widely available, intensifying price negotiation.
Buyers can reduce purchases by adopting alternatives or antibiotic-free programmes.
Threat of Substitutes: High
Probiotics, prebiotics, enzymes, organic acids, phytogenics and butyrates increasingly replace preventive antibiotic use.
Vaccines against diseases such as ileitis, mycoplasma and coccidiosis reduce the need for therapeutic medication.
Water-soluble and injectable formulations compete for therapeutic treatment of the same diseases.
Competitive Rivalry: High
Global animal health companies compete with cost-competitive Chinese and Indian producers on largely generic molecules.
The market is mature in North America and Europe, so share gains come mainly at the expense of competitors.
Competition extends to services, registrations and bundled health programmes.
Threat of New Entrants: Low; Regulatory dossiers, GMP fermentation capacity and scale economies.
Bargaining Power of Suppliers: Medium; Commodity inputs, but concentrated active ingredient supply in China.
Bargaining Power of Buyers: High; Large integrators, generic molecules and the option to switch to alternatives.
Threat of Substitutes: High; Gut health additives, vaccines and alternative administration routes.
Competitive Rivalry: High; Generic competition, price pressure and mature markets in the West.
Market estimates by geography (2032)
InsightAsia Pacific leads with $291.64M by 2032, while Middle East & Africa is projected to grow fastest at a 6.1% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $62.70M | $72.88M | $84.96M | 3.1% | 16% |
| Europe | $14.76M | $16.71M | $21.03M | 3.6% | 4% |
| Asia Pacific | $179.96M | $230.35M | $291.64M | 4.9% | 55% |
| Latin America | $55.20M | $72.01M | $93.55M | 5.4% | 18% |
| Middle East & Africa | $19.11M | $25.81M | $34.66M | 6.1% | 7% |
| Total | $331.73M | $417.76M | $525.85M | 4.7% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$525.85M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Polypeptides & Others | $265.00M | 4.9% | 50% |
| Tetracyclines | $145.30M | 3.5% | 28% |
| Macrolides | $115.55M | 6.2% | 22% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Feed Antibiotics Market covering market dynamics, competitive landscape, and strategic outlook.
The Feed Antibiotics Market market is projected to reach $525.85M by 2032, growing at 4.7% CAGR. The Polypeptides & Others segment holds the largest share.
The feed antibiotics market is influenced by an interplay of demand-side growth and regulatory restraint:
Demand side: rising animal protein consumption, the intensification of poultry and swine production, and persistent disease pressure support continued use of medicated feed.
Regulatory side: antimicrobial resistance policies, consumer preferences and the growing availability of alternatives limit the scope and volume of use.
This chapter assesses these forces through a growth factor analysis and a discussion of drivers, restraints, opportunities, trends and challenges. The impact scores in the growth factor analysis below are analyst assessments, rated on a scale of 1 (minimal impact) to 10 (very strong impact) for three time windows within the forecast period.
Rising Global Demand for Animal Protein
Global consumption of poultry meat, pork, eggs and aquaculture products continues to rise with population growth, urbanisation and higher disposable incomes, especially in Asia, Latin America, the Middle East and Africa. Poultry is the main beneficiary because of its short production cycle, favourable feed conversion and broad cultural acceptance. Producers in India, Southeast Asia, Brazil, Saudi Arabia and Sub-Saharan Africa are scaling up broiler and layer capacity, and each additional flock or herd raises the absolute requirement for disease control. Medicated feed remains one of the most practical ways to treat large groups of animals when a bacterial disease is diagnosed in a flock or herd, particularly where water medication systems are less developed. This structural growth in livestock output is the main reason that Poultry, at USD 171.44 million in 2025, is projected to grow at 5.47% through 2032, faster than the overall market. Rising animal numbers in emerging economies offset the volume reductions achieved through stewardship in mature markets, sustaining overall value growth of 4.71% per year.
Intensification and Consolidation of Livestock Production
Livestock production is shifting from backyard and smallholder systems to large, integrated operations. Examples include the restructuring of the Chinese swine industry after African swine fever, the growth of vertically integrated broiler companies in India and Brazil, and large-scale poultry projects in Saudi Arabia. High stocking densities increase the risk of rapid disease transmission, so integrators rely on structured health programmes that include diagnostically guided medicated feed. Integrated operations also purchase through professional feed mills, which can incorporate premixes accurately and document use as required by veterinary oversight rules. This professionalisation supports demand for registered, quality-assured feed antibiotic products and favours established suppliers with technical service capabilities. It also contributes to steady demand for Swine, which is valued at USD 133.34 million in 2025 and grows at a CAGR of 3.85%.
Persistent Bacterial Disease Pressure in Poultry and Swine
Necrotic enteritis caused by Clostridium perfringens in broilers, swine dysentery and ileitis in pigs, and porcine and avian respiratory complexes involving mycoplasma all remain major causes of economic loss. When the EU and other markets restricted therapeutic zinc oxide and growth promoters, outbreaks of some enteric conditions became harder to manage without targeted therapy. Macrolides such as tylosin, tilmicosin and tylvalosin, and polypeptides such as bacitracin and enramycin, are widely used against these diseases. This underpins the above-market growth of Macrolides (CAGR 6.10%) and the large base of Polypeptides & Others (USD 190.49 million in 2025). Veterinary diagnostics and metaphylactic protocols increasingly determine when and which product is used, which supports demand for effective molecules even as overall usage becomes more targeted.
Expanding Feed Industry and Animal Health Investment in Emerging Markets
Feed milling capacity and animal health distribution networks are expanding across India, Southeast Asia, the Middle East, Africa and Latin America. Food security strategies in the Gulf states, for example, support domestic poultry production, while Indian and Brazilian integrators continue to invest in feed mills and hatcheries. Global and regional animal health companies are responding by opening affiliates in high-growth markets. Huvepharma, for instance, established affiliates in South Korea (2022), Indonesia and the Philippines (2023) and Malaysia (2025). Better distribution and registration coverage improves access to licensed premixes and gradually displaces informal or unregistered products. This is reflected in the strong growth of Middle East & Africa (CAGR 6.10%) and Latin America (CAGR 5.38%).
Growth of Poultry Production in High-Growth Emerging Markets
Saudi Arabia (CAGR 7.58%), India (CAGR 7.50%) and the UAE are the fastest-growing country markets, each driven by poultry. National poultry self-sufficiency programmes, growing integrator networks and improving veterinary infrastructure create room for registered therapeutic products. Suppliers that combine local registrations, veterinary technical support and reliable supply can gain share quickly in these markets.
Label Expansion and Lifecycle Management of Established Molecules
Manufacturers are extending approvals of established molecules to new species, indications and production stages. Jinhe Biotechnology obtained approval for chlortetracycline premix in sheep in 2024, with approvals for other species under review. ECO Animal Health received an updated U.S. label in October 2023 allowing Aivlosin (tylvalosin) in breeding females. Label expansion of this kind increases the usable market without requiring entirely new active substances, which are rarely developed for in-feed use.
Integrated Health Programmes and Stewardship Services
Leading companies increasingly offer feed antibiotics as part of integrated health programmes that combine diagnostics, vaccines, anticoccidials and nutritional specialties. Usage-monitoring and stewardship support services help producers meet regulatory and customer requirements, and they create differentiation in a market otherwise dominated by generic molecules. Phibro's combination of medicated feed additives with vaccines and nutritional specialties is an example of this model.
Regulatory Restrictions on Growth Promotion and Prophylactic Use
Regulators have systematically narrowed the permitted uses of antibiotics in feed:
European Union: antibiotic growth promoters have been banned since 2006. Regulations (EU) 2019/6 and 2019/4, applicable from 28 January 2022, prohibit routine prophylactic use of antimicrobials in groups of animals and restrict prophylactic use of medicated feed.
United States: growth-promotion uses of medically important antimicrobials ended in January 2017 under FDA Guidance for Industry #209 and #213, and their remaining in-feed uses require a Veterinary Feed Directive.
China: MARA Announcement No. 194 ended the use of growth-promoting drug feed additives in commercial feed from 1 July 2020.
Brazil and India: Brazil has banned specific molecules as growth promoters, and India banned colistin for food-producing animals in 2019.
These measures limit volume growth and shift demand towards prescription-only therapeutic use. Their effect is visible in the slower growth of North America (CAGR 3.11%).
Consumer Preference for Antibiotic-Free Production
Retailers, quick-service restaurant chains and consumers in North America, Europe and increasingly in Asia favour poultry and pork raised without antibiotics or with reduced antibiotic use. Labelled antibiotic-free programmes remove the treated animals from the premium supply chain, which discourages the use of medicated feed even where it is clinically justified. This preference also accelerates investment in alternatives such as probiotics, enzymes, organic acids and vaccines, reducing the addressable volume for feed antibiotics.
Competition from Non-Antibiotic Alternatives
Gut health solutions, including probiotics, prebiotics, essential oils, organic acids, enzymes, butyrate products and autogenous and commercial vaccines, increasingly perform the preventive role historically filled by low-dose antibiotics. Feed additive majors are investing heavily in these categories, and their adoption reduces the frequency of medicated feed interventions in well-managed operations.
Challenge: Antimicrobial Resistance and Long-Term Regulatory Uncertainty
Resistance concerns, including the detection of transferable colistin resistance and resistance to macrolides and tetracyclines in zoonotic bacteria, keep feed antibiotics under scrutiny. Any further reclassification of molecules as reserved for human use, as under Commission Implementing Regulation (EU) 2022/1255, could remove products from specific markets at short notice. This uncertainty makes long-term planning and investment difficult for manufacturers.
Trend: Consolidation of Medicated Feed Additive Portfolios
Ownership of medicated feed additive portfolios has been consolidating. Zoetis divested its medicated feed additive portfolio to Phibro Animal Health in a transaction completed on 31 October 2024. The portfolio comprised more than 37 product lines and six manufacturing sites. Elanco divested its aqua business to Merck Animal Health in July 2024. Companies are concentrating either on specialised feed additive portfolios or on innovative pharmaceuticals and biologics, which is reshaping the competitive landscape.
Trend: Capacity Expansion by Chinese Active Ingredient Producers
Chinese manufacturers continue to expand fermentation capacity and integrate backwards. Jinhe Biotechnology's sixth-phase plant received veterinary GMP certification in January 2025, raising total chlortetracycline premix capacity to 115,000 tonnes per year. China Animal Husbandry Industry agreed in March 2026 to acquire controlling stakes in Shengxue Dacheng, a veterinary antibiotic active ingredient producer. These moves strengthen China's role as the global cost benchmark for key molecules.
Trend: Data-Driven Antimicrobial Use Monitoring
Governments and integrators are building systematic antimicrobial use reporting. Examples include the EMA's ESUAvet reports, the FDA's annual summary reports, WOAH's ANIMUSE database and the UK VARSS reports. This transparency encourages targeted, documented use and favours suppliers that can support compliance.
The feed antibiotics value chain comprises four principal stages.
Raw materials and inputs: Fermentation substrates such as corn starch, glucose, soybean meal and other nitrogen sources; mineral salts; chemical intermediates for semi-synthetic molecules; and premix carriers such as calcium carbonate, rice hulls and wheat middlings. Agricultural commodity and energy prices drive input costs, and several producers integrate backwards into corn processing to secure substrate supply.
Manufacturing: Active ingredients such as chlortetracycline, oxytetracycline, tylosin, bacitracin and enramycin are produced through large-scale fermentation, followed by extraction, purification and drying. Semi-synthetic molecules such as tilmicosin and tylvalosin require additional chemical steps. The active ingredient is then formulated into premixes or Type A medicated articles under veterinary GMP conditions. China hosts a large share of global fermentation capacity, while the U.S., Europe and other regions host formulation sites and specialised plants.
Distribution and channels: Products move to feed mills and integrators through direct sales by manufacturers, veterinary distributors and premix companies. Medicated feed is produced by licensed feed mills on veterinary prescription or a Veterinary Feed Directive, as each market requires. Technical service, registration support and documentation are important value-adding activities at this stage.
End users: Poultry integrators (broilers, layers, turkeys), swine producers, cattle feedlots and dairy operations, small ruminant farms and aquaculture farms use medicated feed under veterinary direction to treat and control bacterial diseases.
North America
United States: The FDA Center for Veterinary Medicine regulates feed antibiotics. Under Guidance for Industry #209 and #213, growth-promotion and feed-efficiency uses of medically important antimicrobials were withdrawn, and their remaining in-feed uses were moved under veterinary oversight from 1 January 2017. The Veterinary Feed Directive (VFD) final rule governs the use of VFD drugs in feed. The FDA also publishes an annual Summary Report on Antimicrobials Sold or Distributed for Use in Food-Producing Animals.
Canada: Since 1 December 2018, Health Canada has required a veterinary prescription for medically important antimicrobials and has removed growth-promotion claims. The Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) monitors sales and use.
Europe
European Union: Antibiotic growth promoters have been banned since 1 January 2006 under Regulation (EC) No 1831/2003. Regulation (EU) 2019/6 on veterinary medicinal products and Regulation (EU) 2019/4 on medicated feed have applied since 28 January 2022. They restrict prophylactic and metaphylactic use, and Regulation (EU) 2019/4 prohibits the use of medicated feed containing antimicrobials for prophylaxis. Commission Implementing Regulation (EU) 2022/1255 designates antimicrobials reserved for human use.
United Kingdom: The Veterinary Medicines Directorate regulates veterinary medicines under the Veterinary Medicines Regulations, as amended in 2024, and publishes annual UK-VARSS reports.
Asia Pacific
China: Ministry of Agriculture and Rural Affairs Announcement No. 194 ended production and import of growth-promoting drug feed additives from 1 January 2020 and their use in commercial feed from 1 July 2020. Therapeutic premixes require veterinary drug approval.
India: Gazette notification S.O. 2607(E) of July 2019 prohibits colistin and its formulations for food-producing animals, poultry, aquaculture and animal feed supplements.
Japan: Antibacterial feed additives are regulated under the Act on Safety Assurance and Quality Improvement of Feeds, administered by the Ministry of Agriculture, Forestry and Fisheries.
Latin America
Brazil: The Ministry of Agriculture (MAPA) banned colistin as a growth promoter in 2016. Instrução Normativa nº 1 of January 2020 prohibits tylosin, lincomycin and tiamulin as performance enhancers.
Regional trend: Other Latin American regulators, including Argentina's SENASA, are aligning veterinary antimicrobial controls with WOAH and Codex Alimentarius guidance.
Middle East & Africa
South Africa: Stock remedies, including certain in-feed antibiotics, are registered under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act (Act 36 of 1947). Veterinary medicines fall under the Medicines and Related Substances Act (Act 101 of 1965).
Regional trend: Gulf Cooperation Council countries regulate veterinary products through national food and drug and agriculture authorities and are progressively strengthening registration and residue monitoring.
International Standards
The Codex Alimentarius Code of Practice to Minimize and Contain Foodborne Antimicrobial Resistance (CXC 61-2005, revised in 2021).
The WOAH List of Antimicrobial Agents of Veterinary Importance.
The WHO Medically Important Antimicrobials List (2024).
These provide reference frameworks for national regulation.
2022: Huvepharma; Expansion; Opened a representative office in Ukraine and an affiliate in South Korea.
2023: Huvepharma; Expansion; Opened affiliates in Indonesia and the Philippines.
Oct 2023: ECO Animal Health; Approval; Received U.S. FDA approval of a new label allowing Aivlosin water-soluble granules in breeding females; Canada removed matching label restrictions.
Nov 2023: Virbac; Acquisition; Acquired a majority stake in Globion, an Indian poultry vaccine manufacturer.
Feb 2024: Elanco Animal Health / Merck Animal Health; Divestiture / Acquisition; Elanco agreed to sell its aqua business to Merck Animal Health for approximately USD 1.3 billion.
Apr 2024: Zoetis / Phibro Animal Health; Acquisition; Phibro agreed to acquire Zoetis's medicated feed additive portfolio, comprising more than 37 product lines and six manufacturing sites, for USD 350 million.
Apr 2024: Virbac; Acquisition; Acquired Sasaeah, an animal health company in Japan.
Jul 2024: Merck Animal Health; Acquisition; Completed the acquisition of Elanco's aqua business.
Jul 2024: Huvepharma; Partnership; Entered a U.S. sales and marketing collaboration with ADM for ruminant feed additives.
2024: Jinhe Biotechnology; Approval; Obtained approval for chlortetracycline premix use in sheep.
Oct 2024: Phibro Animal Health; Acquisition; Completed the acquisition of the Zoetis medicated feed additive portfolio and certain water-soluble products; the products are sold in approximately 80 countries.
Dec 2024: Shandong Lukang Pharmaceutical; Investment; Announced a private placement of up to RMB 1.2 billion, completed in early 2026.
Jan 2025: Jinhe Biotechnology; Expansion; Sixth-phase plant received veterinary GMP certification, raising chlortetracycline premix capacity to 115,000 tonnes per year.
2025: Huvepharma; Expansion; Opened an affiliate in Malaysia.
Mar 2026: China Animal Husbandry Industry; Acquisition; Won the bid for controlling stakes in Hebei Shengxue Dacheng Pharmaceutical and Inner Mongolia Shengxue Dacheng, veterinary antibiotic active ingredient producers, for RMB 727 million.
Jun 2026: CPBIO Holding; Rebranding; Completed its name change from Chia Tai Enterprises International to CPBIO Holding Company Limited.
Jul 2026: Jinhe Biotechnology; Investment; Shenzhen Stock Exchange accepted its application for an RMB 300 million private placement.
Aug 2026: Shandong Lukang Pharmaceutical; Expansion; Announced RMB 564 million of investment in an active pharmaceutical ingredient manufacturing project and a green biomanufacturing project.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 31 companies operating in the Feed Antibiotics Market market, including revenue, employee count, and market positioning where available.
Showing 31 of 31 companies
Company Headquarters: Carros, Southeastern France, France Founded: 1968 Workforce: ~4825 Company Working: Virbac develops, manufactures, and markets a wide range of veterinary pharmaceutical products and has a market experience of more than fifty years and is one of the top 10 players in the global animal health market. It operates through the livestock and aquaculture business segments, and manufactures products including parasiticides, immunology, antibiotics/dermatology, specialties, equine, and specialized pet food. The company has a presence in more than 100 countries and generates more than 60% of its revenue from outside Europe. It has 11 manufacturing units in different countries and five fully equipped R&D facilities for the development of products.
3 interactive charts drawn from the Feed Antibiotics Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Feed Antibiotics Market By Livestock
Global Feed Antibiotics Market By Antibiotic Class
Global Feed Antibiotics Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
